CA-125

(redirected from CA-125 test)

CA-125

Abbreviation for cancer antigen 125 and the test for it. See: cancer antigen 125 test.

MUC16

A gene on chromosome 19p13.2 which encodes a protein that provides a protective lubricating barrier against particles and infectious agents at mucosal surfaces. It is more commonly known as CA125, and is a highly characteristic marker of ovarian carcinomas.

CA-125

A cell surface glycoprotein expressed on the cell membrane of normal ovarian tissue, ovarian, cervical, endometrium, GI tract, and breast CAs; rising levels indicate a poor prognosis, but low levels are of little clinical utility; CA-125 may also be ↑ in liver disease, acute pancreatitis, renal failure, occasionally in normal ♀, lymphoma
References in periodicals archive ?
COMPUTED TOMOGRAPHY IMAGING MARKET FOR CANCER: SALESAND FORECAST, 2012-2018 ($ MILLIONS) 117GLOBAL CA-125 TEST MARKET 117TABLE 64 ELEVATED CA-125 LEVEL 118TABLE 65 GLOBAL DIAGNOSTIC MARKET FOR CA-125 TESTS: SALES ANDFORECAST, THROUGH 2018 ($ MILLIONS) 119FIGURE 10 GLOBAL DIAGNOSTIC MARKET FOR CA-125 TESTS: SALES ANDFORECAST, 2012-2018 ($ MILLIONS) 119U.
The CA-125 test is often elevated in ovarian cancer, a finding that led to considering use of the test for ovarian cancer screening.
The CA-125 test can detect rising levels of this protein and is typically used to see if ovarian cancer has come back.
But don't bet your life on this when the CA-125 test is so readily available.
The disadvantages of using the CA-125 test as a screening tool are its lack of specificity and its inability to detect early cancers.
While one marker of ovarian cancer--the antigen CA-125--has been found, screening the public at large has not been recommended, since the poor specificity of the CA-125 test, combined with the cancer's low prevalence, would result in a high rate of false positives.
The most commonly used test, the CA-125 test, detects levels of a protein on the surface of many cancer cells.
However, a similar test developed by researchers at the National Cancer Institute had a specificity and sensitivity of 95% and a positive predictive value of 94%--far greater accuracy rates than the CA-125 test.
No accuracy data have been released for OvaCheck, given that validity testing is underway, but a similar test developed by researchers at the National Cancer Institute had a specificity and sensitivity of 95% and a positive predictive value of 94%--far greater accuracy rates than the CA-125 test.
The CA-125 test is used to monitor response to therapy or detect recurrence as well as make an initial diagnosis.
Other studies that used screening protocols starting with a CA-125 test found that it detected 16%-30% of stage I ovarian cancers.